Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in...

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Aggressive platelet inhibition is vital for reducing myocardial injury post-coronary intervention.
• Observational studies suggest higher clopidogrel loading doses may improve efficacy, but this lacks randomized trial evidence.

Purpose of the Study:

• To evaluate the efficacy and safety of a 600-mg versus 300-mg clopidogrel loading dose in patients undergoing percutaneous coronary intervention.
• To determine the impact on periprocedural myocardial infarction and cardiac events.

Main Methods:

• A randomized trial involving 255 patients undergoing percutaneous coronary intervention.
• Patients received either a 600-mg (n=126) or 300-mg (n=129) clopidogrel loading dose 4-8 hours pre-procedure.
• Primary endpoint: 30-day incidence of death, myocardial infarction (MI), or target vessel revascularization.

Main Results:

• The primary endpoint occurred in 4% of the 600-mg group vs. 12% in the 300-mg group (P=0.041), driven by periprocedural MI.
• Peak cardiac biomarker levels (CK-MB, troponin I, myoglobin) were significantly lower with the 600-mg dose (P≤0.038).
• The 600-mg dose was associated with a 50% MI risk reduction (OR 0.48, P=0.044); safety profiles were similar.

Conclusions:

• Pretreatment with a 600-mg clopidogrel loading dose is safe and superior to the 300-mg dose for reducing periprocedural MI in PCI patients.
• These findings support a potential shift in antiplatelet therapy practices before percutaneous revascularization.